%0 Journal Article
%A Guerra Veloz, María Fernanda
%A Cordero Ruiz, Patricia
%A Ríos-Villegas, María José
%A Del Pino Bellido, Pilar
%A Bravo-Ferrer, José
%A Galvés Cordero, Rocío
%A Cadena Herrera, María Lorena
%A Vías Parrado, Carmen
%A Bellido Muñoz, Francisco
%A Vega Rodríguez, Francisco
%A Caunedo Álvarez, Ángel
%A Rodríguez-Baño, Jesús
%A Carmona Soria, Isabel
%T Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection
%D 2021
%@ 1130-0108
%U http://hdl.handle.net/10668/3957
%X Introduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due to cirrhosis-associated immune dysfunction. The aim of this study was to determine the prevalence of CLD in COVID-19 patients and to analyze the course of the infection, com pared with patients with non-liver disease. Materials and methods: this was a retrospective single cen ter study of all patients with a positive SARS-CoV-2 poly merase chain reaction (PCR) test from March 23rd to April 30th, 2020. Clinical and biochemical data of patients with and without CLD and COVID-19 were collected from the medical records. Result: four hundred and forty-seven patients with a SARS CoV-2 positive PCR were included, 6.3 % had CLD; 69.7 % of patients with CLD were male, with a median age of 65.5 years and active alcohol consumption and smoking; 75 % had non-advanced liver fibrosis and most had non-alcoholic fatty liver disease (NAFLD). The hospital admission rate (92.9 % vs 47.7 %, p < 0.001), concomitant comorbidities (diabetes 38.5 vs 16.5 %, p = 0.011; obesity 30.8 vs 8.5 %, p = 0.033; cancer 23.1 vs 5 %, p = 0.027; and chronic obstructive pulmonary disease (COPD) 19.2 vs 9 %, p = 0.009) and con comitant antibiotics treatment (19.3 vs 5 %, p = 0.018) were higher in patients with CLD than in those without CLD. In patient hospital mortality rates were similar in both groups (30.8 vs 19.6 %, p = 0.289). The presence of CLD was not associated with mortality (OR = 1.06; 95 % CI = 0.35-3.18; p = 0.924). However, patients with CLD and COVID-19 who were male, obese or under concomitant antibiotic treat ment had the highest risk of mortality according to the uni variate analysis. Conclusion: patients with CLD had a higher risk of hospi tal admission, with worse outcomes during the COVID-19 infection associated to other concomitant comorbidities and a suspicion of bacterial co-infection.
%K SARS-CoV-2
%K Chronic liver disease
%K Advanced fibrosis
%K Hospital admission rate
%K Mortality
%K Hepatopatía terminal
%K Fibrosis
%K Pruebas de admisón rutinarias
%K Mortalidad
%~